CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial Dec 03, 2019 8:00am EST
CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model Nov 21, 2019 6:00am EST
CytoDyn's Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies Nov 19, 2019 6:00am EST
CytoDyn Announces Acceptance of Leronlimab (PRO 140) Data for Presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2020 Nov 18, 2019 6:00am EST
CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on November 14, 2019 Nov 13, 2019 8:02pm EST
CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer Nov 12, 2019 10:14pm EST
First Patient in CytoDyn’s Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size Nov 11, 2019 8:02pm EST
